title: Management of Epidermolytic Ichthyosis in the Newborn.
abstract: Epidermolytic ichthyosis (EI) is a rare autosomal dominant genodermatosis that presents at birth as a bullous disease, followed by a lifelong ichthyotic skin disorder. Essentially, it is a defective keratinization caused by mutations of keratin 1 (KRT1) or keratin 10 (KRT10) genes, which lead to skin fragility, blistering, and eventually hyperkeratosis. Successful management of EI in the newborn period can be achieved through a thoughtful, directed, and interdisciplinary or multidisciplinary approach that encompasses family support. This condition requires meticulous care to avoid associated morbidities such as infection and dehydration. A better understanding of the disrupted barrier protection of the skin in these patients provides a basis for management with daily bathing, liberal emollients, pain control, and proper nutrition as the mainstays of treatment. In addition, this case presentation will include discussions on the pathophysiology, complications, differential diagnosis, and psychosocial and ethical issues.
authors: Mondell
authors: M
authors: Avril
authors: Cheryl
authors: C
authors: Riley
mesh_terms: D000700:Analgesics / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D019468:Disease Management; D004750:Enteral Nutrition / Q000379:methods*; D006801:Humans; D017488:Hyperkeratosis, Epidermolytic / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D007231:Infant, Newborn; D053556:Keratin-1 / Q000235:genetics*; D008297:Male; D009154:Mutation; D010348:Patient Care Team; D017592:Skin Care / Q000379:methods*
chemical_list: D000700:Analgesics; D000900:Anti-Bacterial Agents; C491616:KRT1 protein, human; D053556:Keratin-1